Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 25 tags : Positive save search
Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific Meeting
Published: 2021-10-25 (Crawled : 14:00) - biospace.com/
FNCH | $2.205 -6.57% -7.03% 30K
|
Professional, Scientific, and T...
|
| O: -0.9%
H: 7.94%
C: 7.86%
positive trial
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
AQST | $4.11 -8.67% -9.49% 2.3M
|
Health Technology
|
| O: 1.64%
H: 9.45%
C: 7.6%
phase 1 positive topline trial phase 2 phase 3
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergi
Published: 2021-10-25 (Crawled : 13:00) - aquestive.com
AQST | $4.11 -8.67% -9.49% 2.3M
|
Health Technology
|
| O: 1.64%
H: 9.45%
C: 7.6%
treatment epinephrine phase 1 positive topline drug trial merge
Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: -1.69%
H: 6.93%
C: 6.78%
covid phase 2 phase 2/3 positive children vaccine topline
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergic Reactions
Published: 2021-10-25 (Crawled : 13:00) - globenewswire.com
AQST | $4.11 -8.67% -9.49% 2.3M
|
Health Technology
|
| O: 1.64%
H: 9.45%
C: 7.6%
treatment epinephrine phase 1 positive topline drug trial merge
Taysha Gene Therapies Announces Publication of Positive Proof-of-Concept Preclinical Data for an AAV-mediated UBE3A Gene Replacement
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: -3.46%
H: 4.94%
C: 1.27%
media gene therapies positive preclinical gene therapy therapy pre-clinical
Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.1%
H: 0.86%
C: 0.78%
treatment positive results trials phase 3 trial hiv topline injection infections
Solutions 30 resumes its external growth policy and strengthens its position in the United Kingdom
Published: 2021-10-25 (Crawled : 07:00) - globenewswire.com
ERIC | News | $5.1 0.79% 0.78% 19M
|
Electronic Technology
|
| O: -4.6%
H: 0.5%
C: -0.59%
growth positive
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.